Skip to Content
Main Content

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts large, multi-institutional trials to improve outcomes of cellular therapies, such as hematopoietic cell transplantation (HCT), cellular vaccines, and chimeric antigen receptor T cells (CAR-T) for patients facing life-threatening disorders. Established in 2001, the BMT CTN infrastructure facilitates the participation of a large network of centers in trials available to patients in all regions of the US.

The BMT CTN's mission is to evaluate promising therapeutic approaches in multi-institutional clinical trials to improve the outcomes of blood and bone marrow transplantation and other cellular therapies for patients facing life-threatening blood disorders. The Data and Coordinating Center of the BMT CTN is managed by 3 organizations with extensive cellular therapy research experience:

What the BMT CTN offers

  • Scientific expertise. The BMT CTN is led by global experts in the field of cellular therapy who work together to achieve common goals.
  • Extensive network. The BMT CTN encompasses a network of 39 core / consortia and more than 75 affiliate centers across the US.
  • Efficient protocol process. The BMT CTN has a well-functioning infrastructure for rapid implementation and completion of trials, and leaders in the field provide ongoing input as the protocol is developed.
  • Accrual success. BMT CTN trials have accrued more than 16,500 patients. Among the Network-led protocols currently open, the overall accrual rate is 96% of target projections.
  • Biorepository and clinical trial data resources. The BMT CTN accepts applications for ancillary and correlative studies using not only clinical trial outcome data associated with completed trials but also biospecimens from the Network's Research Sample Repository.
  • Proven history of dissemination. BMT CTN investigators regularly publish manuscripts in peer-reviewed journals and present abstracts at national and international meetings.


The BMT CTN offers a range of multi-institutional Phase II and III clinical trial protocols focused directly on improving patient outcomes and advancing the science of cellular therapy. The Network has answered important questions in both common and rare diseases. Our research portfolio includes studies in leukemia, myelodysplasia, lymphoma, and multiple myeloma as well as rare transplant indications, such as aplastic anemia, sickle cell disease, human immunodeficiency virus (HIV)-associated cancers, and hemophagocytic syndromes / primary immune deficiencies. Network trials address critical issues in optimal graft sources, conditioning intensity, regimen-related toxicity, engraftment, graft-versus-host disease (GVHD), infection, disease control, and quality of life. Learn more about these protocols through the links below or visit the BMT CTN website to get the most recent protocol list.

Resources for Investigators

The BMT CTN offers resources to support investigators participating in the network. The BMT CTN website provides additional information, including:

Visit the BMT CTN website to learn more about this research and how to get involved.


Skip to Results Listing


Please wait while we gather your results.